Cover Image

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Fei Gao, Holly Janes, Susan Buchbinder, Deborah Donnell
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Statistics in Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Active-Controlled Trial Design for HIV Prevention Trials with a Counterfactual Placebo
by: Gao, Fei, et al.
Published: (2024)

A General Framework for Designing and Evaluating Active‐Controlled Trials with Non‐Inferiority Objectives
by: Antonio Olivas‐Martinez, et al.
Published: (2026)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
by: Ethan Ashby, et al.
Published: (2025)

Proximal Learning for Trials With External Controls: A Case Study in HIV Prevention
by: Song, Yilin, et al.
Published: (2026)

The Design of Large‐Scale Plasma Donation Trials
by: Kecheng Li, et al.
Published: (2025)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
by: Shu Jiang, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
by: Daniel Backenroth, et al.
Published: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
by: Yuwei Cheng, et al.
Published: (2026)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
by: Kendra Davis‐Plourde, et al.
Published: (2025)

On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
by: Pavla Krotka, et al.
Published: (2026)

Bayesian Response‐Adaptive Randomization for Cluster Randomized Controlled Trials
by: Yunyi Liu, et al.
Published: (2026)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
by: Jingya Gao, et al.
Published: (2024)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
by: Yuan Li, et al.
Published: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
by: Yingjie Qiu, et al.
Published: (2026)

Dynamic Borrowing With a Bias‐Tolerance Cap in Augmented Randomized Controlled Trials
by: Kota Sawada, et al.
Published: (2026)

Semiparametric Estimation of Relative Causal Effects in Randomized Controlled Trials With Noncompliance
by: Wenli Liu, et al.
Published: (2025)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
by: David S. Robertson, et al.
Published: (2025)

Futility Monitoring in Clinical Trials
by: Ana M. Ortega‐Villa, et al.
Published: (2025)

RMST for Interval‐Censored Data in Oncology Clinical Trials
by: Xiyuan Gao, et al.
Published: (2025)

Group Sequential Trial Design Using Stepwise Monte Carlo for Increased Flexibility and Robustness
by: Amitay Kamber, et al.
Published: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

A Framework for Generating Realistic Synthetic Tabular Data in a Randomized Controlled Trial Setting
by: Niki Z. Petrakos, et al.
Published: (2025)

Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials
by: Jingyan Fu, et al.
Published: (2025)

An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing With Concurrent Controls in Platform Trials
by: Tianyu Zhan, et al.
Published: (2025)

Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials
by: Antonio D'Alessandro, et al.
Published: (2026)

Estimation and Hypothesis Testing of Strain‐Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID‐19 Vaccine Trial
by: Fei Heng, et al.
Published: (2025)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
by: Daniel E. Schwartz, et al.
Published: (2026)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
by: Tianyu Zhan, et al.
Published: (2026)

Model‐Robust Standardization in Cluster‐Randomized Trials
by: Fan Li, et al.
Published: (2025)

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial
by: Corine Baayen, et al.
Published: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
by: Cheng‐Han Yang, et al.
Published: (2026)

Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation
by: Junichi Asano, et al.
Published: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
by: Yichen Yan, et al.
Published: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
by: Hyejung Jung, et al.
Published: (2026)

Two‐Stage Double‐Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region
by: Jiashan He, et al.
Published: (2026)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
by: Holger Dette, et al.
Published: (2025)

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
by: Erik W. van Zwet, et al.
Published: (2026)